Alcon Announces US Launch of Tryptyr for Dry Eye Disease
Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin prescribing Tryptyr to their patients.
A first-in-class TRPM8 receptor agonist (neuromodulator), Tryptyr stimulates corneal sensory nerves to rapidly increase natural tear production. Tryptyr demonstrated statistically significant increase in natural tear production as early as Day 1.[1,2]
To view EyewireTV's coverage of the FDA approval of Tryptyr, including an interview with Jonathan Balch, General Manager of the Global Ocular Health & Pharmaceuticals business at Alcon, click here.
“Tryptyr is highly anticipated in the dry eye disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” Lisa Praeger, Vice President, General Manager, U.S. Ocular Health Pharmaceutical, Alcon, said in a company news release. “As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to eye care professionals and the millions of patients who need dry eye disease relief. Leveraging our deep commercial expertise and specialized sales force, we’re excited to give broader access to this important new treatment option.”
Alcon also announced the launch of an ECP campaign, which will focus on the speed of rapid natural tear production with Tryptyr. The campaign features ECP tools, including videos and an interactive website, along with a patient website. Additionally, Alcon recently hosted a national broadcast event for ECPs, featuring conversations surrounding this DED treatment option.
According to Alcon, the US launch will coincide with expansive access initiatives, including a full field access management team dedicated to assisting ECPs with fulfillment, and a 'First Fill Free' trial program for eligible Tryptyr patients. Additionally, ongoing copay support will be offered for refills for eligible patients.
For ECPs interested in more information on Tryptyr, visit https://tryptyr.myalcon.com/professional/.
References
- Data on File for COMET-2 Phase 3 Study. Alcon 2025.
- Data on File for COMET-3 Phase 3 Study. Alcon 2025.